|
http://ept.irmau.com/irm/Company/ShowPage.aspx?CPID=1444 Company Announcement Dr Aston appointed to Biological Committee of Government IR&D Board Melbourne, Australia July 10th, 2007 Clinuvel Pharmaceuticals Limited (ASX: CUV, Germany-XETRA:UR9) is pleased to announce that Dr Roger Aston, Clinuvel’s Executive Chairman has been appointed as a member of the Biological Committee of the Industry Research and Development Board. Dr Aston was appointed to the Board by The Hon Ian Macfarlane, Australia’s Minister for Industry, Tourism and Resources. The Board was established on 1 July 1986, under the Industry Research and Development Act 1986. Its mission is to increase the economic return from successful technology-based enterprises in Australia by guiding the Australian Government's investment in the commercialisation of the nation's research and development and innovation. The Biological Committee assesses Commercial Ready applications, and variations to R&DStart and BIF grants, and makes recommendations for grant funding involving products, processes or services in the following industries: health, medical sciences, agriculture, fishing, forestry, environmental, food-processing. (Source: www.ausindustry.gov.au) About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Limited (ASX:CUV, XETRA/DAX:UR9, ADR:CUVLY) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments. The five indications are: Indication Description Clinical Trial Status Polymorphic Light Eruption (PLE / PMLE) Sun poisoning Phase III trials began May 2007 Erythropoietic Protoporphyria (EPP) Absolute sun intolerance Phase III trials began June 2007 Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients Non-melanoma skin cancers / precursor to skin cancers Phase II trials planned to begin 2007 Solar Urticaria (SU) Acute anaphylactic reaction to sun Phase II trials planned to begin 2007 Phototoxicity associated with Photodynamic Therapy (PDT) Photo-sensitivity associated with cancer treatment Phase II trials planned to begin 2007 Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date. Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647. -END |
|
| aus der Diskussion: | CLINUVEL PHARMACEUTICALS LTD |
| Autor (Datum des Eintrages): | derneureiche (10.07.07 09:53:38) |
| Beitrag: | 57 von 22,251 (ID:30608783) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |